BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wong YJ, Thurairajah PH, Kumar R, Fock KM, Law NM, Chong SY, Manejero FG, Ang TL, Teo EK, Tan J. The impact of unrestricted access to direct-acting antiviral among incarcerated hepatitis C virus-infected patients. Clin Mol Hepatol 2021;27:474-85. [PMID: 33601868 DOI: 10.3350/cmh.2021.0015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Loo JH, Xu WXF, Low JT, Tay WX, Ang LS, Tam YC, Thurairajah PH, Kumar R, Wong YJ. Efficacy and safety of sofosbuvir/velpatasvir with or without ribavirin in hepatitis C genotype 3 compensated cirrhosis: A meta-analysis. World J Hepatol 2022; 14(6): 1248-1257 [DOI: 10.4254/wjh.v14.i6.1248] [Reference Citation Analysis]
2 Supanan R, Han WM, Harnpariphan W, Ueaphongsukkit T, Ubolyam S, Sophonphan J, Tangkijvanich P, Thanprasertsuk S, Avihingsanon A; HIV-NAT HCV Study Team. Brief Report: HCV Universal Test-and-Treat With Direct Acting Antivirals for Prisoners With or Without HIV: A Prison Health Care Workers-Led Model for HCV Microelimination in Thailand. J Acquir Immune Defic Syndr 2021;88:465-9. [PMID: 34757974 DOI: 10.1097/QAI.0000000000002801] [Reference Citation Analysis]